Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03736018
Other study ID # Reda 012466
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 15, 2018
Est. completion date September 30, 2023

Study information

Verified date December 2022
Source Queen Mary University of London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A large number of patients with symptomatic ischaemic heart disease undergo coronary artery bypass grafting (CABG) to alleviate their symptoms and improve prognosis. Given the progressive nature of coronary disease, bypass grafts can narrow or block over time, leading to chest pain and the need for further invasive coronary angiography. Invasive coronary procedures in patients with bypass grafts can be more complicated due to the variation in bypass graft ostia. This can lead to longer procedure times, with higher doses of contrast and radiation and more discomfort for the patient. The aim of this study is to see if the use of computed tomography cardiac angiography (CTCA) in patients with previous bypass grafts prior to invasive coronary angiography will help make their procedure safer and quicker.


Description:

The BYPASS-CTCA trial is a single-centre, randomised controlled trial, which plans to recruit 688 patients who have had previous bypass grafts and require invasive coronary angiography over a period of 30 months. Patients will be randomised to receive either computed tomography cardiac angiography (CTCA) prior to their invasive coronary angiogram, or invasive coronary angiography alone. The primary endpoints will be the incidence of contrast induced nephropathy, the duration of the invasive coronary angiographic procedure and patient satisfaction. A number of secondary endpoints will also be looked at. Findings from BYPASS-CTCA will potentially demonstrate that a CTCA prior to invasive coronary angiography in this cohort of patients reduces the incidence of contrast-induced kidney injury, the length of procedure and improves patients satisfaction. The results of this trial may influence future clinical practice guidelines in coronary artery bypass graft patients undergoing invasive coronary procedures.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 688
Est. completion date September 30, 2023
Est. primary completion date August 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients undergoing invasive coronary angiogram +/- percutaneous coronary Intervention 2. Previous Coronary Artery Bypass Grafting (CABG) 3. Aged =18 4. Patients able and willing to give their written informed consent. Exclusion Criteria: 1. Subjects presenting with ST elevation myocardial infarction, cardiogenic shock (systolic blood pressure <80 mmHg for >30 minutes, or requiring inotropes or emergency intra aortic balloon pump for hypotension treatment) or cardiopulmonary resuscitation. 2. Subjects with eGFR <20ml/min or on renal replacement therapy. 3. Current life-threatening condition other than vascular disease that may prevent a subject completing the study. 4. Clinical instability including cardiogenic shock, hypotension (low blood pressure-systolic blood pressure less than 90 mmHg), sustained ventricular or atrial arrhythmia requiring intravenous medications. 5. Inability to tolerate beta-blockers, including those with chronic obstructive pulmonary disease or asthma, complete heart block, second-degree atrioventricular block 6. Known contrast dye allergy. 7. Pregnancy or unknown pregnancy status. 8. Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures). 9. Inability or refusal to provide informed consent. 10. Any inclusion criteria not met

Study Design


Intervention

Diagnostic Test:
CTCA
Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).

Locations

Country Name City State
United Kingdom Barts Health NHS Trust London

Sponsors (1)

Lead Sponsor Collaborator
Queen Mary University of London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Procedural duration Length of invasive coronary angiogram Interval between administration of local anaesthesia for obtaining vascular access and removal of the last catheter
Primary Incidence of Contrast Induced Nephropathy Defined by Kidney Disease: Improving Global outcomes (KDIGO) criteria 48-72hours
Primary Patient satisfaction Patient satisfaction measured by validated questionnaire 4-6hours
Secondary Contrast amount Contrast amount (mls) administered during invasive coronary angiogram From time of arterial sheath insertion to removal of arterial catheters
Secondary Radiation exposure Radiation exposure (mSv) during invasive coronary angiogram From time of arterial sheath insertion to removal of arterial catheters
Secondary Angiography related complications Angiography related complications (coronary or aortic dissection, stroke, bleeding, vascular access complications) 4-6hours
Secondary Radial access rate Radial access rates during invasive coronary angiogram From time of randomisation to end of invasive coronary angiogram procedure
Secondary Catheters used Number of catheters used during invasive coronary angiogram From time of arterial sheath insertion to removal of arterial catheters
Secondary Computed Tomography Cardiac Angiography accuracy Accuracy of the Computed Tomography Cardiac Angiography scan for detecting graft patency From time of randomisation to end of invasive coronary angiogram procedure
Secondary Number of grafts not identified Number of grafts not identified during invasive coronary angiogram From time of arterial sheath insertion to removal of arterial catheters
Secondary Cost effectiveness of computed tomography cardiac angiography Incremental Cost Effectiveness Ratio (ICER) 12 months
See also
  Status Clinical Trial Phase
Terminated NCT04877847 - Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury N/A
Recruiting NCT02088502 - Theophylline, N-acetylcysteine, and Theophylline Plus N-acetylcysteine in Preventing Contrast-induced Nephropathy Phase 2/Phase 3
Completed NCT03329443 - The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography Phase 2
Recruiting NCT04864847 - Clinical Validation of the RENISCHEM L-FABP POC Assay
Completed NCT03627130 - The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy Phase 2
Withdrawn NCT04603261 - Time to Excretion of Contrast, a Maastricht Prospective Observational Study
Withdrawn NCT04598516 - Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30
Recruiting NCT03755700 - Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization Phase 3
Active, not recruiting NCT04606056 - Risk of Acute Kidney Injury After Intravenous Contrast Computed Tomography Scans
Terminated NCT02440646 - Natural History of Coronary Atherosclerosis in Real-World Stable Chest Pain Patients Underwent Computed Tomography Angiography in Comparison With Invasive Multimodality Imaging
Completed NCT00175227 - Prevention of Contrast-Induced Nephropathy N/A
Completed NCT04014153 - CI-AKI in Patients With Stable CAD and Comorbidities. Are we Doing Better?
Withdrawn NCT04597892 - Efficacy of Point-Of-Care Creatinine Assays in Patients With eGFR <30 Receiving Intravascular Contrast
Completed NCT03305874 - Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization
Not yet recruiting NCT01871792 - Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction Phase 4
Not yet recruiting NCT06429345 - Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients. Phase 4
Recruiting NCT05271448 - Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography N/A
Withdrawn NCT03806725 - Safety of Iodinated Contrast in Liver Transplant Candidates With Decreased Renal Function Undergoing Coronary CT Angiography
Completed NCT04163250 - Use of Urinary Cell-Cycle Arrest Biomarkers in Contrast-Associated Nephropathy After Coronary Angiography
Completed NCT04225013 - Early Diagnosis as Strategy in Reducing the Incidence of Contrast-induced Nephropathy